49. 全身性エリテマトーデス Systemic lupus erythematosus Clinical trials / Disease details

臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

9 trials found

diseases per page:

Showing 1 to 9 of 9 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05624749 (ClinicalTrials.gov)	March 7, 2023	7/11/2022	Phase 3 Study to Evaluate Ianalumabon Top of Standard-of-care Therapy in Patients With Systemic Lupu ...	A Randomized, Double-blind, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safet ...	Systemic Lupus Erythematosus	Drug: ianalumab;Drug: placebo	Novartis Pharmaceuticals	NULL	Not yet recruiting	12 Years	N/A	All	280	Phase 3	NULL
2	NCT05639114 (ClinicalTrials.gov)	March 1, 2023	4/11/2022	Phase 3 Study to Evaluate Two Regimens of Ianalumabon Top of Standard-of-care Therapy in Patients Wi ...	A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate ...	Systemic Lupus Erythematosus	Drug: Ianalumab;Drug: Placebo	Novartis Pharmaceuticals	NULL	Not yet recruiting	12 Years	N/A	All	406	Phase 3	NULL
3	EUCTR2022-002691-36-SK (EUCTR)	07/02/2023	24/10/2022	Phase 3 study to evaluate two regimens of ianalumabon top of standard-of-care therapy in patients wi ...	A randomized, double-blind, parallel group, placebo-controlled multicenter phase 3 study to evaluate ...	Systemic Lupus Erythematosus MedDRA version: 21.1;Level: PT;Classification code 10042945;Term: Syste ...	Product Name: ianalumab Product Code: VAY736 INN or Proposed INN: IANALUMAB Other descriptive name: VAY ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	406	Phase 3	Hungary;United States;Czechia;Japan;Thailand;Portugal;Spain;Canada;Czech Republic;Turkey;China;Brazi ...
4	EUCTR2022-002691-36-CZ (EUCTR)	27/01/2023	23/11/2022	Phase 3 study to evaluate two regimens of ianalumabon top of standard-of-care therapy in patients wi ...	A randomized, double-blind, parallel group, placebo-controlled multicenter phase 3 study to evaluate ...	Systemic Lupus Erythematosus MedDRA version: 21.1;Level: PT;Classification code 10042945;Term: Syste ...	Product Name: ianalumab Product Code: VAY736 INN or Proposed INN: IANALUMAB Other descriptive name: VAY ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	406	Phase 3	Portugal;United States;Czechia;Slovakia;Thailand;Spain;Guatemala;Turkey;Israel;Hungary;Czech Republi ...
5	EUCTR2022-002691-36-ES (EUCTR)	22/12/2022	01/11/2022	Phase 3 study to evaluate two regimens of ianalumabon top of standard-of-care therapy in patients wi ...	A randomized, double-blind, parallel group, placebo-controlled multicenter phase 3 study to evaluate ...	Systemic Lupus Erythematosus MedDRA version: 21.1;Level: PT;Classification code 10042945;Term: Syste ...	Product Name: ianalumab Product Code: VAY736 INN or Proposed INN: IANALUMAB Other descriptive name: VAY ...	Novartis Farmacéutica, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	406	Phase 3	Portugal;United States;Czechia;Slovakia;Spain;Thailand;Guatemala;Turkey;Israel;Hungary;Canada;Brazil ...
6	EUCTR2018-001508-12-FR (EUCTR)	05/02/2019	13/11/2018	Study the efficacy and safety of VAY736 and CFZ533 in patients with systemic lupus erythematosus (SL ...	A placebo-controlled, patient and investigator blinded, randomized parallel cohort study to assess p ...	Systemic lupus erythematosus (SLE) MedDRA version: 20.0;Level: PT;Classification code 10042945;Term: ...	Product Code: VAY736 INN or Proposed INN: ianalumab Other descriptive name: VAY736 Product Code: CFZ533 ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	120	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	Taiwan;Spain;Thailand;Russian Federation;Israel;France;Czech Republic;Hungary;Argentina;Poland;Austr ...
7	EUCTR2018-001508-12-ES (EUCTR)	12/12/2018	09/10/2018	Study the efficacy and safety of VAY736 and CFZ533 in patients with systemic lupus erythematosus (SL ...	A placebo-controlled, patient and investigator blinded, randomized parallel cohort study to assess p ...	Systemic lupus erythematosus (SLE) MedDRA version: 20.0;Level: PT;Classification code 10042945;Term: ...	Product Code: VAY736 INN or Proposed INN: ianalumab Other descriptive name: VAY736 Product Code: CFZ533 ...	Novartis Farmacéutica, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	120	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	Taiwan;Spain;Thailand;Russian Federation;Israel;France;Czech Republic;Hungary;Argentina;Poland;Austr ...
8	EUCTR2018-001508-12-DE (EUCTR)	05/12/2018	28/08/2018	Study the efficacy and safety of VAY736 and CFZ533 in patients with systemic lupus erythematosus (SL ...	A placebo-controlled, patient and investigator blinded, randomized parallelcohort study to assess ph ...	Systemic lupus erythematosus (SLE) MedDRA version: 21.1;Level: PT;Classification code 10042945;Term: ...	Product Code: VAY736 INN or Proposed INN: ianalumab Other descriptive name: VAY736 Product Code: CFZ533 ...	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	135	Phase 2	United States;Czechia;Taiwan;Spain;Thailand;Israel;Russian Federation;France;Czech Republic;Hungary; ...
9	EUCTR2018-001508-12-CZ (EUCTR)	02/11/2018	28/08/2018	Study the efficacy and safety of VAY736 and CFZ533 in patients with systemic lupus erythematosus (SL ...	A placebo-controlled, patient and investigator blinded, randomized parallelcohort study to assess ph ...	Systemic lupus erythematosus (SLE) MedDRA version: 21.1;Level: PT;Classification code 10042945;Term: ...	Product Code: VAY736 INN or Proposed INN: ianalumab Other descriptive name: VAY736 Product Code: CFZ533 ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	135	Phase 2	Argentina;Russian Federation;Hungary;Japan;Thailand;Spain;Czech Republic;China;Taiwan;Korea, Republi ...

First Previous1Next Last